Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Biomarkers in chronic kidney disease: a review.

Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE.

Kidney Int. 2011 Oct;80(8):806-21. doi: 10.1038/ki.2011.198. Epub 2011 Jun 22. Review.

2.

Biomarkers of renal function, which and when?

Wasung ME, Chawla LS, Madero M.

Clin Chim Acta. 2015 Jan 1;438:350-7. doi: 10.1016/j.cca.2014.08.039. Epub 2014 Sep 3. Review.

PMID:
25195004
3.

Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease.

Spanaus KS, Kollerits B, Ritz E, Hersberger M, Kronenberg F, von Eckardstein A; Mild and Moderate Kidney Disease (MMKD) Study Group.

Clin Chem. 2010 May;56(5):740-9. doi: 10.1373/clinchem.2009.138826. Epub 2010 Mar 11.

4.

Clinical review: Biomarkers of acute kidney injury: where are we now?

Ostermann M, Philips BJ, Forni LG.

Crit Care. 2012 Sep 21;16(5):233. doi: 10.1186/cc11380. Review.

5.

Biomarkers in acute and chronic kidney disease.

Nickolas TL, Barasch J, Devarajan P.

Curr Opin Nephrol Hypertens. 2008 Mar;17(2):127-32. doi: 10.1097/MNH.0b013e3282f4e525. Review.

PMID:
18277143
6.

Urinary biomarkers for the detection of renal injury.

Rosner MH.

Adv Clin Chem. 2009;49:73-97. Review.

PMID:
19947356
7.

Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population.

Astor BC, Shafi T, Hoogeveen RC, Matsushita K, Ballantyne CM, Inker LA, Coresh J.

Am J Kidney Dis. 2012 May;59(5):653-62. doi: 10.1053/j.ajkd.2011.11.042. Epub 2012 Feb 4.

9.

Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.

Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M.

Clin J Am Soc Nephrol. 2009 Feb;4(2):337-44. doi: 10.2215/CJN.03530708. Epub 2009 Jan 28.

10.

NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction.

Holzscheiter L, Beck C, Rutz S, Manuilova E, Domke I, Guder WG, Hofmann W.

Clin Chem Lab Med. 2014 Apr;52(4):537-46. doi: 10.1515/cclm-2013-0693.

PMID:
24243749
11.

Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD).

Smith ER, Lee D, Cai MM, Tomlinson LA, Ford ML, McMahon LP, Holt SG.

Nephrol Dial Transplant. 2013 Jun;28(6):1569-79. doi: 10.1093/ndt/gfs586. Epub 2013 Jan 16.

12.

Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease.

Devarajan P.

Scand J Clin Lab Invest Suppl. 2008;241:89-94. doi: 10.1080/00365510802150158. Review.

13.

Biomarkers for early detection of sickle nephropathy.

Sundaram N, Bennett M, Wilhelm J, Kim MO, Atweh G, Devarajan P, Malik P.

Am J Hematol. 2011 Jul;86(7):559-66. doi: 10.1002/ajh.22045. Epub 2011 May 31.

14.

Novel biomarkers indicating repair or progression after acute kidney injury.

Kashani K, Kellum JA.

Curr Opin Nephrol Hypertens. 2015 Jan;24(1):21-7. doi: 10.1097/MNH.0000000000000090. Review.

PMID:
25415614
15.

Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA).

Peralta CA, Katz R, Bonventre JV, Sabbisetti V, Siscovick D, Sarnak M, Shlipak MG.

Am J Kidney Dis. 2012 Dec;60(6):904-11. doi: 10.1053/j.ajkd.2012.05.014. Epub 2012 Jun 30.

16.

Biomarkers of nephrotoxic acute kidney injury.

Ferguson MA, Vaidya VS, Bonventre JV.

Toxicology. 2008 Mar 20;245(3):182-93. doi: 10.1016/j.tox.2007.12.024. Epub 2008 Jan 4. Review.

17.

Implications of the changes in serum neutrophil gelatinase-associated lipocalin and cystatin C in patients with chronic kidney disease.

Shen SJ, Hu ZX, Li QH, Wang SM, Song CJ, Wu DD, He JL, Guan JC, Shan JP.

Nephrology (Carlton). 2014 Mar;19(3):129-35. doi: 10.1111/nep.12203.

PMID:
24397346
18.

Subclinical and clinical contrast-induced acute kidney injury: data from a novel blood marker for determining the risk of developing contrast-induced nephropathy (ENCINO), a prospective study.

Akrawinthawong K, Ricci J, Cannon L, Dixon S, Kupfer K, Stivers D, Alexander P, David S, McCullough PA.

Ren Fail. 2015 Mar;37(2):187-91. doi: 10.3109/0886022X.2014.991994. Epub 2014 Dec 18.

PMID:
25519207
19.

Clinical application of neutrophil gelatinase-associated lipocalin in the revised chronic kidney disease classification.

Xiang D, Zhang H, Bai J, Ma J, Li M, Gao J, Wang C.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):7172-81. eCollection 2014.

20.

Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the Atherosclerosis Risk in Communities (ARIC) Study.

Bhavsar NA, Köttgen A, Coresh J, Astor BC.

Am J Kidney Dis. 2012 Aug;60(2):233-40. doi: 10.1053/j.ajkd.2012.02.336. Epub 2012 Apr 28.

Items per page

Supplemental Content

Write to the Help Desk